Serina Therapeutics, Inc.
SER- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001708599
No open-market purchases or sales by Serina Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.73M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $38.1M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 27
- 13F valueReported value at the end of Q2 2026
- $2.73M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $130.0K
- +132.1% year over year
- Net income, FY2025
- -$19.2M
- No comparable prior period
- Free cash flow, FY2025
- -$18.0M
- No comparable prior period
- Revenue, Q2 FY2026
- $0
- −100.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $19.2M (14755.4% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 46.8K
- Shares sold short
- Change
- +2.92K
- +6.7% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding SER, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding SER at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Serina Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 (view filing)12:05 PM ET | Jul 7 | 2 days | Brannan Stephen K.Director | PPurchase | +1.00K | $2.03 | +$2.03K | New position1.00K after | |
| Jun 22, 2026 (view filing) | May 22 | 31 daysLate | Venkatesan JayDirector | PPurchase | +589 | $1.78 | +$1.05K | New position589 after | |
| Jun 15, 2026 (view filing) | Jun 11-12 | 4 days | Wilson Karen JDirector | PPurchase | +10.1K | $1.76 | +$17.8K | New position10.1K after | 2 lots |
| May 26, 2026 (view filing) | May 21-22 | 5 days | Wilson Karen JDirector | PPurchase | +20.0K | $1.85 | +$37.0K | New position20.0K after | 2 lots |
| May 22, 2026 (view filing) | May 19 | 3 daysLate | Marshall Richard PeterDirector | PPurchase | +12.2K | $1.65 | +$20.1K | New position12.2K after | |
| Mar 24, 2026 (view filing)7:24 PM ET | Mar 23 | 1 day | Moreadith RandallChief Scientific Officer | SSale | −6.50K | $2.86 | −$18.6K | −100.0%0 after | 10b5-1 |
| Mar 20, 2026 (view filing)2:20 PM ET | Mar 19 | 1 day | Moreadith RandallChief Scientific Officer | SSale | −39.0K | $2.50 | −$97.5K | −100.0%0 after | 10b5-1 |
| Feb 3, 2026 (view filing)12:35 PM ET | Feb 2 | 1 day | Moreadith RandallChief Scientific Officer | SSale | −6.50K | $3.03 | −$19.7K | −100.0%0 after | 10b5-1 |
| Jan 29, 2026 (view filing)12:54 PM ET | Jan 28 | 1 day | Moreadith RandallChief Scientific Officer | SSale | −6.50K | $3.57 | −$23.2K | −100.0%0 after | 10b5-1 |
| Jan 23, 2026 (view filing)12:35 PM ET | Jan 22 | 1 day | Moreadith RandallChief Scientific Officer | SSale | −2.50K | $2.95 | −$7.38K | −100.0%0 after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 27 holdersThe largest institutional positions in Serina Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sio Capital Management, LLC | 1,000,000 | $1.94M | 0.33% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 162,198 | $314.7K | 0.00% | +3,062+1.9% | Added |
| Warren Averett Asset Management, LLC | 67,492 | $130.9K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 51,007 | $99.0K | 0.00% | −13,966−21.5% | Reduced |
| Keel Point, LLC | 21,508 | $41.7K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 20,771 | $40.3K | 0.00% | +20,771 | New |
| Vanguard Fiduciary Trust Co | 20,009 | $38.8K | 0.00% | 00.0% | Unchanged |
| Avidian Wealth Solutions, LLC | 18,800 | $36.5K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 15,444 | $30.0K | 0.00% | −24,209−61.1% | Reduced |
| State Street Corp | 12,758 | $24.8K | 0.00% | 00.0% | Unchanged |
Holders of 5% or more of SER
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Serina Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Juvenescence Ltd | 13D/A | 27.30%4.40M shares | – | Jan 12, 202133 filings | Jul 22, 2026 | SEC |
| Sio Capital Management, LLC | 13G/A | 7.87%2.00M shares | +1.16 ppfrom 6.71% | May 4, 20262 filings | Nov 3, 2026 | SEC |